Cedar Brook Financial Partners’s GSK GSK Stock Holding History

Cedar Brook Financial Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,198	Closed	-$245K	–	330
2020 Q3	$245K	Hold	5,198	–	–	0.1%	236
2020 Q2	$265K	Buy	5,198 +36	+0.7%	+$1.85K	0.12%	211
2020 Q1	$244K	Sell	5,162 -8	-0.2%	-$427	0.14%	193
2019 Q4	$304K	Buy	5,170 +24	+0.5%	+$1.33K	0.13%	201
2019 Q3	$275K	Sell	5,146 -67	-1%	-$3.45K	0.12%	219
2019 Q2	$261K	Sell	5,213 -2	-0%	-$100	0.12%	229
2019 Q1	$272K	Sell	5,215 -35	-0.7%	-$1.75K	0.13%	212
2018 Q4	$251K	Buy	+5,250	New	+$259K	0.15%	188

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Cedar Brook Financial Partners's GSK Position: Q4 2020 in Review

Cedar Brook Financial Partners sold out of GSK (GSK) in Q4 2020, closing a stake of 5,198 shares — an estimated $245K sold.

Cedar Brook Financial Partners first reported a position in GSK in Q4 2018 and held it in 8 quarters. The position peaked at $304K in Q4 2019. 818 funds tracked by Wall St. Rank hold GSK as of Q4 2020.

Cedar Brook Financial Partners reported no remaining GSK position as of Q4 2020 after selling out during the quarter.
Cedar Brook Financial Partners sold 5,198 GSK shares in Q4 2020, an estimated $245K.
Cedar Brook Financial Partners first reported a position in GSK in Q4 2018 and held it in 8 quarters.
Cedar Brook Financial Partners's GSK position peaked at $304K in Q4 2019.
818 funds tracked by Wall St. Rank held GSK as of Q4 2020.

Based on Cedar Brook Financial Partners's 13F filing for Q4 2020, filed 12 Feb 2021.